Thelansis

 Chemotherapy-induced peripheral neuropathy (CIPN) stands out as a prevalent adverse effect triggered by antineoplastic medications, with its occurrence ranging from 19% to over 85%. It primarily manifests as sensory nerve damage, accompanied by varying degrees and durations of motor and autonomic alterations. Given its high occurrence among cancer patients, CIPN poses a significant challenge for patients, survivors, and their healthcare providers. This is primarily due to the absence of a single effective method to prevent CIPN. Central sensitization is pivotal in neuropathic pain, especially from nerve damage. The harm to peripheral nerves, particularly C-fibers, results in spontaneous activity that disrupts secondary neurons in the spinal dorsal horn, leading to heightened excitability due to various molecular changes. Clinically, CIPN manifests as sensory, motor, and autonomic deficits of varying severity. Sensory symptoms usually initiate the condition, typically affecting the...

  Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common side effects caused by antineoplastic agents, with a prevalence ranging from 19% to over 85%. CIPN is predominantly sensory neuropathy accompanied by motor and autonomic changes of varying intensity and duration. Because of its high prevalence among cancer patients, CIPN constitutes a significant problem for both cancer patients and survivors and their health care providers, mainly because, at the moment, there is no single effective method of preventing CIPN. Central sensitization plays a role in pain, particularly in neuropathic pain. The literature suggested the involvement of a wide array of neurons, ion channels, signaling pathways, molecules, and non-neuronal cells in central sensitization. Damage to peripheral nerves (particularly C-fibers) causes spontaneous activity, which alters secondary order neurons in the spinal dorsal horn and results in hyper-excitability via various molecular changes. ...